Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice

Endocrinology

Volumn 157, Issue 2, 2016, Pages 570-585

  Wilson, Camella G ^a   Tran, Jennifer L ^a   Erion, Derek M ^b   Vera, Nicholas B ^b   Febbraio, Maria ^c   Weiss, Ethan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD36 ANTIGEN; CHOLESTEROL ESTER; DIACYLGLYCEROL; FATTY ACID; INSULIN; JANUS KINASE 2; OLEIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE DELETION; GENE DISRUPTION; GENETIC MODEL; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID LIVER LEVEL; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTIBODY SPECIFICITY; GENETICS; KNOCKOUT MOUSE; LIVER; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY;

ANIMALS; ANTIGENS, CD36; DIET, HIGH-FAT; FATTY ACIDS, NONESTERIFIED; HEPATOCYTES; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGAN SPECIFICITY; TRIGLYCERIDES;

EID: 84956932380     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1866     Document Type: Article

References (41)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-1231.
2. Doege H, Baillie RA, Ortegon AM, et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology. 2006;130(4):1245-1258.
3. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004;39(4):909-914.
4. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut. 2003;52(6):914.
5. Langendonk JG, Meinders AE, Burggraaf J, et al. Influence of obesity and body fat distribution on growth hormone kinetics in humans. Am J Physiol. 1999;277(5 Pt 1):E824-E829.
6. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284(30): 19937-19944.
7. Sos BC, Harris C, Nordstrom SM, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest. 2011;121(4):1412-1423.
8. Cui Y, Hosui A, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 2007;46(2):504-513.
9. Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268(16): 11811-11816.
10. Febbraio M, Guy E, Coburn C, Knapp FF Jr, Beets AL, Abumrad NA, et al. The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36. Mol Cell Biochem. 2002;239(1-2):193-197.
11. Ibrahimi A, Bonen A, Blinn WD, et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem. 1999;274(38):26761-26766.
12. Bechmann LP, Gieseler RK, Sowa JP, et al. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 2010;30(6):850-859.
13. Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in nonalcoholic steatohepatitis and chronic hepatitis C. Gut. 2011;60(10): 1394-1402.
14. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008; 294(5):G1281-G1287.
15. Su X, Abumrad NA. Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol Metab. 2009;20(2):72-77.
16. Koonen DP, Jacobs RL, Febbraio M, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56(12):2863-2871.
17. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR[gamma] in promoting steatosis. Gastroenterology. 2008;134(2):556-567.e551.
18. Hui ST, Parks BW, Org E, et al. The genetic architecture of NAFLD among inbred strains of mice. Elife. 2015;4:e05607.
19. Coburn CT, Knapp FF Jr, Febbraio M, Beets AL, Silverstein RL, Abumrad NA. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem. 2000;275(42):32523-32529.
20. Hajri T, Han XX, Bonen A, Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest. 2002;109(10):1381-1389.
21. Wilson CG, Schupp M, Burkhardt BR, Wu J, Young RA, Wolf BA. Liver-specific overexpression of pancreatic-derived factor (PANDER) induces fasting hyperglycemia in mice. Endocrinology. 2010; 151(11):5174-5184.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC[T]) method. Methods. 2001;25(4):402-408.
23. Khalifeh-Soltani A, McKleroy W, Sakuma S, et al. Mfge8 promotes obesity by mediating the uptake of dietary fats and serum fatty acids. Nat Med. 2014;20(2):175-183.
24. Nagendran J, Pulinilkunnil T, Kienesberger PC, et al. Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery. J Mol Cell Cardiol. 2013;63:180-188.
25. Coburn C, Hajri T, Ibrahimi A, Abumrad N. Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues. J Mol Neurosci. 2001;16(2):117-121.
26. Krammer J, Digel M, Ehehalt F, Stremmel W, Füllekrug J, Ehehalt R. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. Int J Med Sci. 2011;8(7):599-614.
27. Goudriaan JR, Dahlmans VE, Teusink B, t al. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res. 2003;44(12):2270-2277.
28. Bieghs V, Wouters K, van Gorp PJ, et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology. 2010;138(7):2477-2486, 2486.e2471-e2473.
29. Steyn FJ, Leong JW, Huang L, et al. GH does not modulate the early fasting-induced release of free fatty acids in mice. Endocrinology. 2012;153(1):273-282.
30. Newberry EP, Xie Y, Kennedy S, et al. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem. 2003;278(51): 51664-51672.
31. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014; 510(7503):84-91.
32. Savage DB, Choi CS, Samuel VT, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 2006;116(3):817-824.
33. Dominici FP, Cifone D, Bartke A, Turyn D. Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone-transgenic mice. J Endocrinol. 1999;161(3):383-392.
34. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113(1):96-105.
35. Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274(27):19055-19062.
36. Nassir F, Adewole OL, Brunt EM, Abumrad NA. CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice. J Lipid Res. 2013;54(11): 2988-2997.
37. Clugston RD, Yuen JJ, Hu Y, et al. CD36-deficient mice are resistant to alcohol- and high-carbohydrate-induced hepatic steatosis. J Lipid Res. 2014;55(2):239-246.
38. Ma Y, Huang Y, Yan L, Gao M, Liu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res. 2013;30(5):1447-1457.
39. Steneberg P, Sykaras AG, Backlund F, Straseviciene J, Söderström I, Edlund H. Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. J Biol Chem. 2015;290(31):19034-19043.
40. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004; 279(31):32345-32353.
41. ∈ prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007;117(3):739-745.